지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2019.1
- 수록면
- 74 - 78 (5page)
이용수
초록· 키워드
오류제보하기
Sorafenib is a well-known approved systemic therapeutic agent used in patients with advanced hepatocellular carcinoma (HCC). Regorafenib and nivolumab are approved as second-line therapeutic drugs in patients showing disease progression after sorafenib therapy. However, there is no established third- or fourth-line therapy in patients with progression after regorafenib or nivolumab treatment. Recently, the combination of tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICPIs) has been attempted as a firstline treatment strategy in advanced HCC patients based on the hypothesis that combination therapy may overcome resistance in ICPI monotherapy. On the basis of this suggestion, we herein describe the case of an HCC patient demonstrating macrovascular invasion, whereby partial remission was achieved via the combination of sorafenib and nivolumab following disease progression after nivolumab therapy. Further studies on the combination of TKIs and ICPIs are necessary to determine ways to manage HCC patients showing disease progression after ICPI therapy.
목차
등록된 정보가 없습니다.
참고문헌 (8)
참고문헌 신청
Cheng AL / 2012 / Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial / Eur J Cancer 48:1452~1465
Bruix J / 2012 / Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial / J Hepatol 57:821~829
Bruix J / 2017 / Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, doubleblind, placebo-controlled, phase 3 trial / Lancet 389:56~66
Marrero JA / 2018 / Diagnosis, staging, and management of hepatocellular carcinoma:2018 practice guidance by the american association for the study of liver diseases / Hepatology 68:723~750
Hughes PE / 2016 / Targeted therapy and checkpoint immunotherapy combinations for the treatment of cancer / Trends Immunol 37:462~476
Bruix J / 2012 / Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial / J Hepatol 57:821~829
Bruix J / 2017 / Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, doubleblind, placebo-controlled, phase 3 trial / Lancet 389:56~66
Marrero JA / 2018 / Diagnosis, staging, and management of hepatocellular carcinoma:2018 practice guidance by the american association for the study of liver diseases / Hepatology 68:723~750
Hughes PE / 2016 / Targeted therapy and checkpoint immunotherapy combinations for the treatment of cancer / Trends Immunol 37:462~476
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Nivolumab for Advanced Hepatocellular Carcinoma with Multiple Lung Metastases after Sorafenib Failure
Journal of Liver Cancer
2020 .01
-
Systemic therapy for advanced hepatocellular carcinoma: consideration for selecting second-line treatment
Journal of Liver Cancer
2021 .09
-
Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment
Clinical and Molecular Hepatology
2020 .01
-
Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy
Clinical and Molecular Hepatology
2015 .01
-
Successful Sequential Therapy Involving Regorafenib after Failure of Sorafenib in a Patient with Recurrent Hepatocellular Carcinoma after Liver Transplantation
Journal of Liver Cancer
2020 .01
-
Real-Life Experience of Sorafenib Treatment for Hepatocellular Carcinoma in Korea: From GIDEON Data
Cancer Research and Treatment
2016 .01
-
Infiltrative hepatocellular carcinoma with multiple lung metastasis completely cured using nivolumab: a case report
Journal of Liver Cancer
2021 .09
-
Disease Progression in Chronic Hepatitis B Patients under Long-Term Antiviral Therapy
Gut and Liver
2015 .01
-
Optimal sequence of systemic therapy after sorafenib failure in patients with hepatocellular carcinoma
Clinical and Molecular Hepatology
2020 .01
-
A case report of advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy and sorafenib combination therapy followed by metastasectomy of lung and muscle metastases
Journal of Liver Cancer
2022 .03
-
Down-Regulation of TGF-β Expression Sensitizes the Resistance of Hepatocellular Carcinoma Cells to Sorafenib
Yonsei Medical Journal
2017 .01
-
Extraordinary radiation super-sensitivity accompanying with sorafenib combination therapy: what lies beneath?
Radiation oncology journal : ROJ
2017 .01
-
Current role of proton beam therapy in patients with hepatocellular carcinoma
International Journal of Gastrointestinal Intervention
2021 .10
-
Complete cure of advanced hepatocellular carcinoma with right adrenal gland metastasis and portal vein thrombosis by multiple applications of an interdisciplinary therapy: Case report with 8-year follow up
Clinical and Molecular Hepatology
2018 .01
-
Complete response of advanced hepatocellular carcinoma to sorafenib : another case and a comprehensive review
Clinical and Molecular Hepatology
2017 .01
-
Multidisciplinary treatment with immune checkpoint inhibitors for advanced stage hepatocellular carcinoma
Journal of Liver Cancer
2022 .03
-
Tumor lysis syndrome following sorafenib treatment in hepatocellular carcinoma
영남의대학술지
2015 .01
-
Usefulness of sarcopenia in patients with advanced hepatocellular carcinoma undergoing sorafenib treatment
대한외과학회 학술대회 초록집
2019 .10
-
Recent advances in the management of hepatocellular carcinoma
Clinical and Molecular Hepatology
2024 .01
-
Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Japanese perspective
Clinical and Molecular Hepatology
2023 .04
이 논문의 저자 정보
최근 본 자료
댓글(0)
0